HBeAg-Negative

PegINF alfa-2a versus Lamivudine versus Both
PegINF alfa-2a versus Lamivudine versus Both HBeAg-Negative Patients: Study Design

**Study Features**

Randomized 1:1:1  
HBeAg-negative (N=537)  
HBV DNA >10^5 copies/mL  
ALT >1-10 x ULN  
Treatment x 48 weeks

**Peginterferon alfa-2a:** 180 mcg SC 1/week + Oral Placebo  
(n = 177)

**Peginterferon alfa-2a:** 180 mcg SC 1x/week + Lamivudine: 100 mg/day  
(n = 179)

**Lamivudine:** 100 mg/day  
(n = 181)

PegINF alfa-2a versus Lamivudine versus Both HBeAg-Negative Patients: Results

HBeAg-NEGATIVE Patients: Week 72 Treatment Response

**Conclusions**: “Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates.”